Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,521 to 3,540 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Care Transitions Intervention vs Usual Care: deaths from any cause | 2 of 987 5 of 992 | -0.3 points -1.0 to 0.3 | 1,979 | NCT02520661 Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health |
| Care Transitions Intervention vs Usual Care: serious adverse events | 51 of 987 51 of 992 | 0.0 points -1.9 to 2.0 | 1,979 | NCT02520661 Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health |
| Exubera® vs Non-Exubera®: All-cause Mortality: Number of Deaths | 12 of 987 9 of 989 | 0.3 points -0.7 to 1.3 | 1,976 | NCT00359801 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety |
| Exubera® vs Non-Exubera®: serious adverse events | 124 of 987 109 of 989 | 1.5 points -1.3 to 4.4 | 1,976 | NCT00359801 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 36 (End of Study) Post Enrollment | 53 of 981 58 of 995 | -0.4 points -2.5 to 1.6 | 1,976 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 24 Post Enrollment | 32 of 981 35 of 995 | -0.3 points -1.9 to 1.4 | 1,976 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Evolocumab vs Placebo: serious adverse events | 212 of 983 204 of 990 | 1.0 points -2.6 to 4.6 | 1,973 | NCT02207634 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects |
| Tobacco Quitline Only vs Tobacco Quitline Plus Smoke Free Homes: deaths from any cause | 1 of 987 0 of 986 | 0.1 points -0.3 to 0.6 | 1,973 | NCT04311983 Interventions to Help More Low-income Smokers Quit |
| Pinard vs Doppler: Identification of Abnormal Fetal Heart Rate | 46 of 979 75 of 992 | -2.9 points -5.0 to -0.7 | 1,971 | NCT02273037 Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda |
| Pinard Horn vs Fetal Heart Rate Doppler: Stillbirth and Neonatal Death | 6 of 979 11 of 992 | -0.5 points -1.4 to 0.4 | 1,971 | NCT02273037 Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda |
| Pinard vs Doppler: deaths from any cause | 6 of 979 11 of 992 | -0.5 points -1.4 to 0.4 | 1,971 | NCT02273037 Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda |
| This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 30-day Point Prevalence Abstinence (Responder Only) | 314 of 976 239 of 995 | 8.2 points 4.2 to 12.1 | 1,971 | NCT04251273 Text Message Quit Vaping Intervention for Young Adults |
| Capecitabine vs 5-Fluorouracil + Leucovorin: serious adverse events | 181 of 995 182 of 974 | -0.5 points -3.9 to 2.9 | 1,969 | NCT00009737 A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer |
| This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 7-day Point Prevalence Abstinence (Responder Only) | 440 of 973 385 of 994 | 6.5 points 2.1 to 10.8 | 1,967 | NCT04251273 Text Message Quit Vaping Intervention for Young Adults |
| Cardiovascular Death vs Myocardial Re-infarction: Participants With Cardiac Events During Follow-up. | 92 of 982 51 of 982 | 4.2 points 1.9 to 6.5 | 1,964 | NCT01377402 ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study |
| Liraglutide 1.8 mg vs Oral Antidiabetic Drug: deaths from any cause | 1 of 980 8 of 984 | -0.7 points -1.5 to -0.1 | 1,964 | NCT02730377 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes |
| Liraglutide 1.8 mg vs Oral Antidiabetic Drug: serious adverse events | 92 of 980 81 of 984 | 1.2 points -1.4 to 3.7 | 1,964 | NCT02730377 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes |
| VITALITY 2 vs Medtronic Family: Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit | 246 of 985 187 of 977 | 5.8 points 2.2 to 9.5 | 1,962 | NCT00148954 RIGHT: Rhythm ID Going Head-to-Head Trial |
| Sema 2.4 mg vs Placebo: deaths from any cause | 1 of 1,306 1 of 655 | -0.1 points -0.8 to 0.3 | 1,961 | NCT03548935 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity |
| Sema 2.4 mg vs Placebo: serious adverse events | 128 of 1,306 42 of 655 | 3.4 points 0.8 to 5.8 | 1,961 | NCT03548935 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity |
Code
curl "https://conductscience.org/api/comparisons/v1?page=177"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=177
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02520661-deaths",
"title": "Care Transitions Intervention vs Usual Care: deaths from any cause",
"summary": "2 of 987 against 5 of 992; risk difference -0.3 points, 95% interval -1.0 to 0.3; NCT02520661, Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health",
"record": "/library/comparisons/NCT02520661-deaths",
"nct_id": "NCT02520661",
"kind": "deaths",
"participants": 1979,
"risk_difference": {
"value": -0.0030139801287707942,
"lower": -0.009877498629933342,
"upper": 0.003048493807087101
},
"group_1": "2 of 987",
"group_2": "5 of 992",
"difference": "-0.3 points",
"interval": "-1.0 to 0.3",
"trial_title": "Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health"
},
{
"id": "NCT02520661-sae",
"title": "Care Transitions Intervention vs Usual Care: serious adverse events",
"summary": "51 of 987 against 51 of 992; risk difference 0.0 points, 95% interval -1.9 to 2.0; NCT02520661, Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health",
"record": "/library/comparisons/NCT02520661-sae",
"nct_id": "NCT02520661",
"kind": "serious-adverse-events",
"participants": 1979,
"risk_difference": {
"value": 0.00026044220021570474,
"lower": -0.019479948587876866,
"upper": 0.020023591847744125
},
"group_1": "51 of 987",
"group_2": "51 of 992",
"difference": "0.0 points",
"interval": "-1.9 to 2.0",
"trial_title": "Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=178",
"request_id": "mcUlTILEbEVCPra7"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant